Cerlapirdine

Drug Profile

Cerlapirdine

Alternative Names: Cerlapirdine hydrochloride; PF-05212365; PF-5212365; SAM-531; WAY-262531

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Antidementias
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Schizophrenia

Most Recent Events

  • 01 Apr 2011 Pfizer completes enrolment in its phase II trial for Alzheimer's disease in USA, Europe, Asia, Latin America, New Zealand and South Africa (NCT00895895)
  • 15 Oct 2009 Wyeth has been acquired by Pfizer
  • 05 Oct 2006 Phase-I clinical trials in Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top